Table 3.

Trial results

Group 1Group 2Group 3Group 4Significance*
Placebo/placebo (n = 20)Placebo/celecoxib (n = 21)Exemestane/placebo (n = 19)Exemestane/celecoxib (n = 21)
PrePostPrePostPrePostPrePost
Ki67% Median (range)17.2 (3.1-27.0)13.5 (2.7-28.0)13.5 (3.2-50.0)11.6 (1.8,44.6)20.7 (0.2-52.0)10.1 (.0.5-52.0)19.8 (6.9-49.2)9.3 (0.6-36.6)E: P ≤ 0.001; C: P = 0.26
Apoptosis %, mean (range)1.81 (0.33-6.40)1.81 (0.81-4.70)2.01 (0.38-7.30)2.32 (0.96-7.54)2.02 (0.54-6.50)2.27 (0.92-4.90)2.3 (0.47-9.40)2.05 (0.78-6.10)E: P = 0.99; C: P = 0.82; ExC: P = 0.08
PR %, mean (range)39.7 (0-100)34.9 (0-100)50.7 (0-100)45 (0-100)36.6 (0-100)18.8 (0-90)47.4 (0-100)28.1 (0-100)E: P = 0.011; C:P = 0.61; ExC: P = 0.94
VCAM ng/mL, median (range)494 (245-2,784)419 (262-1,190)417 (245-705)518 (281-950)473 (229-1,007)462 (247-1,085)455 (280-690)495 (362-1,055)E: P = 0.37; C: P = 0.09
VEGF ng/mL, median (range)293 (0-588)257 (0-399)319 (0-957)311 (0-812)326 (0-516)231 (17-422)258 (56-863)184 (12-613)E: P = 0.60; C: P = 0.31

Abbreviations: E, exemestane; C, celecoxib; ExC, interaction.

  • *Ki67%, VCAM, VEGF: Mann-Whitney U tests; Apoptosis %, PR%: ANOVA exemestane versus placebo (group 3 and 4 versus 1 and 2); Ki67 median decrease 9% (95% CI, 6-14; P = 0.001). PR median reduction, 19% (95% CI, 9-28; P = 0.011). Celecoxib versus placebo Ki67 and PR, not significant.